Raynaud Phenomenon Medication: Calcium channel blockers, Prostaglandins, Nitrates, Angina, Phosphodi
Raynaud Phenomenon Medication: Calcium channel blockers, Prostaglandins, Nitrates, Angina, Phosphodiesterase-5 Enzyme Inhibitors, Antidepressants, SSRIs, Endothelin Antagonists, ARBs, Local Anesthetics, Amides, Metabolic & Endocrine, Other, Neuromuscular Blocker Agents, Botulinum Toxins
Drugs in a variety of classes have been studied for use in Raynaud syndrome. None is currently approved for this indication by the US Food and Drug Administration (FDA).
Drugs with clear evidence of benefit shown through randomized controlled trials include calcium channel blockers and the vasodilator iloprost. Other agents used in treatment of Raynaud phenomenon include topical nitroglycerin, the selective serotonin reuptake inhibitor (SSRI) fluoxetine, phosphodiesterase-5 enzyme inhibitors, the endothelin antagonist bosentan, and the angiotensin receptor blocker (ARB) losartan.
These agents are used for vasodilation and possible antiplatelet effects. Calcium channel blockers of the dihydropyridine class contain potent vasodilators and are the first line of treatment after nondrug therapy. Of the dihydropyridines, nifedipine has been extensively studied; however, in the same category, felodipine, amlodipine, and isradipine seem to be equally effective.
Nifedipine inhibits transmembrane influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes without changing serum calcium concentrations; this results in inhibition of cardiac and vascular smooth muscle contraction, with consequent dilation of main coronary and systemic arteries. Vasodilation with decreased peripheral resistance and increased heart rate result.
For Raynaud phenomenon, the extended-release form of nifedipine is most often selected. Treatment should be initiated at the lowest dose available and titrated upward as tolerated, with the goal of diminishing the frequency and/or severity of attacks.
Nicardipine is used for vasodilatation and possible antiplatelet effects. Start with lowest dose available. Extended-release preparations are preferred.
Agents in this class have potent vasodilatory effects.
Iloprost is a synthetic analogue of prostacyclin (prostaglandin I2 [PGI2]) that dilates systemic and pulmonary arterial vascular beds. It is approved for use in pulmonary arterial hypertension, but has been found effective for secondary Raynaud syndrome, administered either orally or intravenously.
Epoprostenol is an analogue of PGI2 that has potent vasodilatory properties, immediate onset of action, and a half-life of approximately 5 minutes. In addition to producing vasodilation, it also contributes to inhibition of platelet aggregation and plays a role in inhibition of smooth muscle proliferation.
Alprostadil (Prostaglandin E1) is used primarily to keep patency of ductus arteriosus but also has a mild pulmonary vasodilatory effect. It is reported to inhibit macrophage activation, neutrophil chemotaxis, and release of oxygen radicals and lysosomal enzymes. It affects coagulation by inhibiting platelet aggregation and possibly by inhibiting activation of factor X. It may promote fibrinolysis by stimulating production of tissue plasminogen activator. Has been found to be effective for secondary Raynaud syndrome.
Topical nitroglycerin is used in Raynaud phenomenon for its local vasodilatory effects.
Topical nitroglycerin is used in Raynaud phenomenon for its local vasodilatory effects.
Phosphodiesterases are a complex group of enzymes that help to tightly regulate the degradation of intracellular cyclic nucleotides. Intracellular responses to both NO and prostacyclin are mediated by the cyclic nucleotides cGMP and cyclic adenosine monophosphate (cAMP), respectively. So, by bolstering the vasodilatory effect of both NO and prostacyclin, these agents may be useful in the treatment of Raynaud phenomenon.
Studies of sildenafil in Raynaud phenomenon have used in doses ranging from 25 mg three times daily to 50 mg twice daily.
Studies of tadalafil in Raynaud phenomenon have used in doses ranging from 20 mg dailiy to 20 mg three times a week. Doses may need to be adjusted for renal or hepatic impairment.
Vardenafil has been used in dosages of 10 mg twice daily for Raynaud phenomenon
Serotonin is a potent vasoconstrictor that is released from nerve endings and during platelet activation. SSRIs do not have consistent evidence showing sustained benefit in Raynaud phenomenon, but they may be chosen if hemodynamic side effects develop with calcium channel blockers or prostacyclin analogues. However, some case reports describe exacerbation of Raynaud syndrome following the initiation of SSRI treatment.
Fluoxetine selectively inhibits presynaptic serotonin reuptake with minimal or no effect in the reuptake of norepinephrine or dopamine. Doses of 20 mg daily have been used in treatment of Raynaud phenomenon, with better results reported in primary Raynaud phenomenon.
Sertraline selectively inhibits presynaptic serotonin reuptake, with minimal or no effect on reuptake of norepinephrine or dopamine.
Citalopram enhances serotonin activity through selective reuptake inhibition at the neuronal membrane. No head-to-head comparisons of SSRIs have been done; however, on the basis of metabolism and adverse effects, citalopram is considered the SSRI of choice for patients with head injury.
Escitalopram is an SSRI and an S-enantiomer of citalopram. It is used for the treatment of depression. Its mechanism of action is thought to be potentiation of serotonergic activity in the CNS, resulting from inhibition of CNS neuronal reuptake of serotonin. The onset of depression relief may be obtained after 1-2 weeks—sooner than is possible with other antidepressants.
These agents inhibit vessel constriction and elevation of blood pressure by competitively binding to endothelin-1 (ET-1) receptors ETA and ETB in endothelium and vascular smooth muscle.
Bosentan is approved for use in the treatment of pulmonary arterial hypertension, but has been used off-label in patients with severe Raynaud phenomenon unresponsive to other therapies. Bosentan is approved in the United Kingdom for the prevention of new digital ulcers in patients with systemic sclerosis.
These agents are used for vasodilation and for their possible antifibrotic and anti-inflammatory effects.
Losartan is a nonpeptide angiotensin II receptor antagonist that blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Short-term treatment at 50 mg/day has proved useful, with better results in patients with systemic sclerosis than in those with primary Raynaud phenomenon.
Candesartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, candesartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Eprosartan is a nonpeptide angiotensin II receptor antagonist that blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, eprosartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Irbesartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II at the tissue receptor site In addition, it does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Losartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, Losartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Olmesartan blocks the vasoconstrictive effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptors in vascular smooth muscle. Its action is independent of the pathways for angiotensin II synthesis.
Valsartan is a prodrug that produces direct antagonism of angiotensin II receptors. It displaces angiotensin II from AT1 receptors and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses.
In addition, it does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Local anesthetics are used for local pain relief. Local infiltration of lidocaine or bupivacaine at the base of the involved digits decreases sympathomimetic input, reduces ischemic pain, and improves blood flow.
Lidocaine is an amide local anesthetic; it inhibits depolarization of type C sensory neurons by blocking sodium channels.
Bupivacaine decreases permeability to sodium ions in neuronal membranes. This results in the inhibition of depolarization, blocking the transmission of nerve impulses.
Agents in this class may be used in patients with systemic sclerosis and digital ulcers.
Acetylcysteine may prevent worsening of baseline renal insufficiency. It may scavenge oxygen-derived free radicals and improve endothelium-dependent vasodilation.
These agents produce symptomatic improvement in strength, autonomic symptoms, or both in some patients.
This agent binds to receptor sites on motor nerve terminals and inhibits the release of acetylcholine, which in turn inhibits the transmission of impulses in neuromuscular tissue.
In patients with rapidly advancing ischemia, anticoagulant therapy may be necessary. Anticoagulants prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation.
Heparin augments the activity of antithrombin III and prevents conversion of fibrinogen to fibrin. It does not actively lyse thrombi but is able to inhibit further thrombogenesis. Heparin prevents recurrence of a clot after spontaneous fibrinolysis.
Heather Hansen-Dispenza, MD Rheumatology Fellow, University of Arizona College of Medicine
Heather Hansen-Dispenza, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology
Coauthor(s)
Jeffrey R Lisse, MD, FACP Professor, Department of Internal Medicine, Chief, Section of Rheumatology, University of Arizona School of Medicine
Jeffrey R Lisse, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American College of Rheumatology, American Geriatrics Society, Sigma Xi
Disclosure: Received consulting fee from Genentech for consulting; Received consulting fee from Centacor for consulting; Received consulting fee from Novartis for review panel membership.
Mayra Oberto-Medina, DO Fellow, Department of Rheumatology, University of Arizona
S Anita Narayanan, MD Fellow in Rheumatology, University of Arizona College of Medicine
S Anita Narayanan, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, American Medical Association
Specialty Editor Board
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine
Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology
Chief Editor
Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa
John Varga, MD Professor, Department of Internal Medicine, Division of Rheumatology, Northwestern University
John Varga, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Central Society for Clinical and Translational Research, Society for Investigative Dermatology
References
A 9-year-old with Raynaud phenomenon. Notice the discoloration of the fingers.
Photo of a patient with Raynaud phenomenon that resulted from working with a jackhammer. Courtesy of the CDC.
Medication Summary
Drugs in a variety of classes have been studied for use in Raynaud syndrome. None is currently approved for this indication by the US Food and Drug Administration (FDA).
Drugs with clear evidence of benefit shown through randomized controlled trials include calcium channel blockers and the vasodilator iloprost. Other agents used in treatment of Raynaud phenomenon include topical nitroglycerin, the selective serotonin reuptake inhibitor (SSRI) fluoxetine, phosphodiesterase-5 enzyme inhibitors, the endothelin antagonist bosentan, and the angiotensin receptor blocker (ARB) losartan.
Calcium channel blockers
Class Summary
These agents are used for vasodilation and possible antiplatelet effects. Calcium channel blockers of the dihydropyridine class contain potent vasodilators and are the first line of treatment after nondrug therapy. Of the dihydropyridines, nifedipine has been extensively studied; however, in the same category, felodipine, amlodipine, and isradipine seem to be equally effective.
Nifedipine (Adalat, Procardia, Nifediac CC, Nifedical XL)
Nifedipine inhibits transmembrane influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes without changing serum calcium concentrations; this results in inhibition of cardiac and vascular smooth muscle contraction, with consequent dilation of main coronary and systemic arteries. Vasodilation with decreased peripheral resistance and increased heart rate result.
For Raynaud phenomenon, the extended-release form of nifedipine is most often selected. Treatment should be initiated at the lowest dose available and titrated upward as tolerated, with the goal of diminishing the frequency and/or severity of attacks.
Nicardipine (Cardene, Cardene SR)
Nicardipine is used for vasodilatation and possible antiplatelet effects. Start with lowest dose available. Extended-release preparations are preferred.
Prostaglandins
Class Summary
Agents in this class have potent vasodilatory effects.
Iloprost (Ventavis)
Iloprost is a synthetic analogue of prostacyclin (prostaglandin I2 [PGI2]) that dilates systemic and pulmonary arterial vascular beds. It is approved for use in pulmonary arterial hypertension, but has been found effective for secondary Raynaud syndrome, administered either orally or intravenously.
Epoprostenol (Flolan, Veletri)
Epoprostenol is an analogue of PGI2 that has potent vasodilatory properties, immediate onset of action, and a half-life of approximately 5 minutes. In addition to producing vasodilation, it also contributes to inhibition of platelet aggregation and plays a role in inhibition of smooth muscle proliferation.
Alprostadil (Prostin VR)
Alprostadil (Prostaglandin E1) is used primarily to keep patency of ductus arteriosus but also has a mild pulmonary vasodilatory effect. It is reported to inhibit macrophage activation, neutrophil chemotaxis, and release of oxygen radicals and lysosomal enzymes. It affects coagulation by inhibiting platelet aggregation and possibly by inhibiting activation of factor X. It may promote fibrinolysis by stimulating production of tissue plasminogen activator. Has been found to be effective for secondary Raynaud syndrome.
Nitrates, Angina
Class Summary
Topical nitroglycerin is used in Raynaud phenomenon for its local vasodilatory effects.
Bosentan (Tracleer)
Topical nitroglycerin is used in Raynaud phenomenon for its local vasodilatory effects.
Phosphodiesterase-5 Enzyme Inhibitors
Class Summary
Phosphodiesterases are a complex group of enzymes that help to tightly regulate the degradation of intracellular cyclic nucleotides. Intracellular responses to both NO and prostacyclin are mediated by the cyclic nucleotides cGMP and cyclic adenosine monophosphate (cAMP), respectively. So, by bolstering the vasodilatory effect of both NO and prostacyclin, these agents may be useful in the treatment of Raynaud phenomenon.
Sildenafil (Revatio)
Studies of sildenafil in Raynaud phenomenon have used in doses ranging from 25 mg three times daily to 50 mg twice daily.
Tadalafil (Adcirca)
Studies of tadalafil in Raynaud phenomenon have used in doses ranging from 20 mg dailiy to 20 mg three times a week. Doses may need to be adjusted for renal or hepatic impairment.
Vardenafil (Levitra, Staxyn ODT)
Vardenafil has been used in dosages of 10 mg twice daily for Raynaud phenomenon
Antidepressants, SSRIs
Class Summary
Serotonin is a potent vasoconstrictor that is released from nerve endings and during platelet activation. SSRIs do not have consistent evidence showing sustained benefit in Raynaud phenomenon, but they may be chosen if hemodynamic side effects develop with calcium channel blockers or prostacyclin analogues. However, some case reports describe exacerbation of Raynaud syndrome following the initiation of SSRI treatment.
Fluoxetine (Prozac)
Fluoxetine selectively inhibits presynaptic serotonin reuptake with minimal or no effect in the reuptake of norepinephrine or dopamine. Doses of 20 mg daily have been used in treatment of Raynaud phenomenon, with better results reported in primary Raynaud phenomenon.
Sertraline (Zoloft)
Sertraline selectively inhibits presynaptic serotonin reuptake, with minimal or no effect on reuptake of norepinephrine or dopamine.
Citalopram (Celexa)
Citalopram enhances serotonin activity through selective reuptake inhibition at the neuronal membrane. No head-to-head comparisons of SSRIs have been done; however, on the basis of metabolism and adverse effects, citalopram is considered the SSRI of choice for patients with head injury.
Escitalopram (Lexapro)
Escitalopram is an SSRI and an S-enantiomer of citalopram. It is used for the treatment of depression. Its mechanism of action is thought to be potentiation of serotonergic activity in the CNS, resulting from inhibition of CNS neuronal reuptake of serotonin. The onset of depression relief may be obtained after 1-2 weeks—sooner than is possible with other antidepressants.
Endothelin Antagonists
Class Summary
These agents inhibit vessel constriction and elevation of blood pressure by competitively binding to endothelin-1 (ET-1) receptors ETA and ETB in endothelium and vascular smooth muscle.
Bosentan (Tracleer)
Bosentan is approved for use in the treatment of pulmonary arterial hypertension, but has been used off-label in patients with severe Raynaud phenomenon unresponsive to other therapies. Bosentan is approved in the United Kingdom for the prevention of new digital ulcers in patients with systemic sclerosis.
ARBs
Class Summary
These agents are used for vasodilation and for their possible antifibrotic and anti-inflammatory effects.
Losartan (Cozaar)
Losartan is a nonpeptide angiotensin II receptor antagonist that blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Short-term treatment at 50 mg/day has proved useful, with better results in patients with systemic sclerosis than in those with primary Raynaud phenomenon.
Candesartan (Atacand)
Candesartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, candesartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Eprosartan (Teveten)
Eprosartan is a nonpeptide angiotensin II receptor antagonist that blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, eprosartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Irbesartan (Avapro)
Irbesartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II at the tissue receptor site In addition, it does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Losartan (Cozaar)
Losartan blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II. In addition, Losartan does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Olmesartan (Benicar)
Olmesartan blocks the vasoconstrictive effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptors in vascular smooth muscle. Its action is independent of the pathways for angiotensin II synthesis.
Valsartan (Diovan)
Valsartan is a prodrug that produces direct antagonism of angiotensin II receptors. It displaces angiotensin II from AT1 receptors and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses.
In addition, it does not affect the response to bradykinin and is less likely to be associated with cough and angioedema.
Local Anesthetics, Amides
Class Summary
Local anesthetics are used for local pain relief. Local infiltration of lidocaine or bupivacaine at the base of the involved digits decreases sympathomimetic input, reduces ischemic pain, and improves blood flow.
Lidocaine (Xylocaine)
Lidocaine is an amide local anesthetic; it inhibits depolarization of type C sensory neurons by blocking sodium channels.
Bupivacaine (Marcaine)
Bupivacaine decreases permeability to sodium ions in neuronal membranes. This results in the inhibition of depolarization, blocking the transmission of nerve impulses.
Metabolic & Endocrine, Other
Class Summary
Agents in this class may be used in patients with systemic sclerosis and digital ulcers.
Acetylcysteine (Acetadote)
Acetylcysteine may prevent worsening of baseline renal insufficiency. It may scavenge oxygen-derived free radicals and improve endothelium-dependent vasodilation.
Neuromuscular Blocker Agents, Botulinum Toxins
Class Summary
These agents produce symptomatic improvement in strength, autonomic symptoms, or both in some patients.
Botulinum toxin type A (BOTOX)
This agent binds to receptor sites on motor nerve terminals and inhibits the release of acetylcholine, which in turn inhibits the transmission of impulses in neuromuscular tissue.
Anticoagulants, Hematologic
In patients with rapidly advancing ischemia, anticoagulant therapy may be necessary. Anticoagulants prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation.
Heparin
Heparin augments the activity of antithrombin III and prevents conversion of fibrinogen to fibrin. It does not actively lyse thrombi but is able to inhibit further thrombogenesis. Heparin prevents recurrence of a clot after spontaneous fibrinolysis.
Heather Hansen-Dispenza, MD Rheumatology Fellow, University of Arizona College of Medicine
Heather Hansen-Dispenza, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology
Coauthor(s)
Jeffrey R Lisse, MD, FACP Professor, Department of Internal Medicine, Chief, Section of Rheumatology, University of Arizona School of Medicine
Jeffrey R Lisse, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American College of Rheumatology, American Geriatrics Society, Sigma Xi
Disclosure: Received consulting fee from Genentech for consulting; Received consulting fee from Centacor for consulting; Received consulting fee from Novartis for review panel membership.
Mayra Oberto-Medina, DO Fellow, Department of Rheumatology, University of Arizona
S Anita Narayanan, MD Fellow in Rheumatology, University of Arizona College of Medicine
S Anita Narayanan, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, American Medical Association
Specialty Editor Board
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine
Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology
Chief Editor
Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa
John Varga, MD Professor, Department of Internal Medicine, Division of Rheumatology, Northwestern University
John Varga, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Central Society for Clinical and Translational Research, Society for Investigative Dermatology
References
- Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008 Oct. 59(4):633-53. [Medline].
- Gayraud M. Raynaud's phenomenon. Joint Bone Spine. 2007 Jan. 74(1):e1-8. [Medline].
- Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug. 8(8):469-79. [Medline].
- Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis. 1996 Feb. 55(2):122-7. [Medline]. [Full Text].
- Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. 2003 Jul. 48(7):1992-2000. [Medline]. [Full Text].
- Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999 Sep. 221(4):312-25. [Medline].
- Sakurai T, Goto K. Endothelins. Vascular actions and clinical implications. Drugs. 1993 Nov. 46(5):795-804. [Medline].
- Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens. 2006 Jun. 24(6):983-91. [Medline].
- Kawaguchi Y, Takagi K, Hara M, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum. 2004 Jan. 50(1):216-26. [Medline].
- Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am. 1996 Nov. 22(4):765-81. [Medline].
- Edwards CM, Marshall JM, Pugh M. Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease. Clin Sci (Lond). 1998 Sep. 95(3):249-60. [Medline].
- Bunker CB, Goldsmith PC, Leslie TA, Hayes N, Foreman JC, Dowd PM. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol. 1996 Mar. 134(3):399-406. [Medline].
- Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet. 1990 Dec 22-29. 336(8730):1530-3. [Medline].
- Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000 Apr. 278(4):H1075-83. [Medline].
- Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 2004 May. 50(5):1578-85. [Medline].
- Lau CS, McLaren M, Saniabadi A, Belch JJ. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol. 1993. 22(3):97-101. [Medline]. [Full Text].
- Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). 2005 May. 44(5):587-96. [Medline]. [Full Text].
- Deshayes S, Auboire L, Jaussaud R, Lidove O, Parienti JJ, Triclin N, et al. Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study. Medicine (Baltimore). 2015 May. 94 (20):e780. [Medline].
- Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 2005 Apr. 52(4):1259-63. [Medline].
- Nietert PJ, Shaftman SR, Silver RM, Wolf BJ, Egan BM, Hunt KJ, et al. Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin Epidemiol. 2015. 7:161-8. [Medline]. [Full Text].
- Purdie GL, Purdie DJ, Harrison AA. Raynaud's Phenomenon in Medical Laboratory Workers Who Work with Solvents. J Rheumatol. 2011 Sep. 38(9):1940-6. [Medline].
- Coulombe J, Powell J, Hatami A, McCuaig C, Renet S, Marcoux D. Diseases of abnormal sensitivity to cold in children on psychostimulant drugs. J Cutan Med Surg. 2014 Oct. 18(5):1-4. [Medline].
- Piotto DG, Hilário MO, Carvalho NS, Len CA, Andrade LE, Terreri MT. Prospective nailfold capillaroscopy evaluation of Raynaud's phenomenon in children and adolescents. Acta Reumatol Port. 2013 Apr-Jun. 38(2):114-21. [Medline].
- Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. Rheumatology (Oxford). 2015 Aug. 54 (8):1443-7. [Medline].
- Generali J, Cada D. Nitroglycerin (topical): Raynaud's phenomenon. Hospital Pharmacy. 2008. 43:980-981. [Full Text].
- Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of Interventions for Secondary Raynaud's Phenomenon: A Systematic Review. Arch Phys Med Rehabil. 2011 Jul. 92(7):1166-80. [Medline].
- Goodfield MJ, Hume A, Rowell NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol. 1990 Apr. 29(2):89-91. [Medline].
- Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul. 48(7):791-5. [Medline].
- Schlager O, Gschwandtner ME, Mlekusch I, Herberg K, Frohner T, Schillinger M, et al. Auricular electroacupuncture reduces frequency and severity of Raynaud attacks. Wien Klin Wochenschr. 2011 Feb. 123(3-4):112-6. [Medline].
- Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2014 Jan 30. 1:CD002069. [Medline].
- Levien TL. Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag. 2010 Mar 24. 6:167-77. [Medline]. [Full Text].
- Kamata Y, Minota S. Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon. Rheumatol Int. 2014 Nov. 34 (11):1623-6. [Medline].
- Gliddon AE, Dore CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007 Nov. 56(11):3837-46. [Medline].
- Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum. 2012 Feb. 41(4):599-603. [Medline].
- Merritt WH. Role and rationale for extended periarterial sympathectomy in the management of severe Raynaud syndrome: techniques and results. Hand Clin. 2015 Feb. 31 (1):101-20. [Medline].
- DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989 Feb. 86(2):158-64. [Medline].
- Roquelaure Y, Ha C, Le Manac'h AP, Bodin J, Bodere A, Bosseau C, et al. Risk factors for Raynaud's phenomenon in the workforce. Arthritis Care Res (Hoboken). 2012 Jun. 64 (6):898-904. [Medline]. [Full Text].
- Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001 Sep. 40(9):1038-43. [Medline]. [Full Text].
- Destors JM, Gauthier E, Lelong S, Boissel JP. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon. Angiology. 1986 Aug. 37(8):565-9. [Medline].
- DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989 Feb. 86(2):158-64. [Medline].
- Dowd PM, Martin MF, Cooke ED, et al. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol. 1982 Jan. 106(1):81-9. [Medline].
- Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999 Dec. 42(12):2646-55. [Medline].
- Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum. 1985 Jan. 28(1):87-92. [Medline].
- Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum. 2008 Jul. 58(7):2174-82. [Medline].
- Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 1993 Jan. 20(1):70-6. [Medline].
- Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, et al. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol. 2014 May. 41 (5):881-6. [Medline].
A 9-year-old with Raynaud phenomenon. Notice the discoloration of the fingers.
Photo of a patient with Raynaud phenomenon that resulted from working with a jackhammer. Courtesy of the CDC.
Source...